The Ozempic lawsuit involving stomach paralysis centers on allegations that Ozempic and other GLP-1 drugs can cause serious gastrointestinal injuries, including gastroparesis, a condition commonly described as stomach paralysis.
Thousands of lawsuits involving GLP-1 drugs have been consolidated in federal court in Pennsylvania under MDL No. 3094. The litigation includes claims involving Ozempic, Wegovy and Rybelsus, made by Novo Nordisk, as well as certain Eli Lilly drugs. Plaintiffs generally allege that the manufacturers failed to adequately warn patients and doctors about the risk of serious gastrointestinal injuries. The manufacturers deny the allegations.
As of 2026, there is no final settlement or approved payout for the Ozempic stomach-paralysis litigation.
What Is the Ozempic Stomach Paralysis Lawsuit?
The lawsuits involve people who say they developed serious gastrointestinal problems after taking GLP-1 medications.
One of the main injuries alleged is gastroparesis.
Gastroparesis occurs when the stomach does not empty food normally into the small intestine. It can cause symptoms such as:
- Nausea
- Vomiting
- Feeling full quickly
- Bloating
- Abdominal pain
- Poor appetite
- Weight changes
- Difficulty eating normally
The lawsuits allege that GLP-1 drugs can contribute to severe or prolonged gastrointestinal problems and that the manufacturers did not adequately warn consumers about these risks. The federal court handling the MDL says the cases raise common questions about whether the manufacturers knew or should have known that their products could cause gastroparesis and other gastrointestinal injuries.
These are allegations, not a final court determination that Ozempic causes gastroparesis in every patient.
What Is Gastroparesis?
Gastroparesis is sometimes called “stomach paralysis,” although the stomach is not literally paralyzed in every case.
The condition involves delayed stomach emptying.
Normally, food moves from the stomach into the small intestine after digestion begins. With gastroparesis, that process becomes abnormally slow.
This can make a person feel full after eating only a small amount.
Severe cases can interfere with nutrition and hydration and may require medical treatment.
Does Ozempic Cause Stomach Paralysis?
Ozempic’s active ingredient is semaglutide, a GLP-1 receptor agonist.
The FDA-approved prescribing information states that Ozempic delays gastric emptying and warns about gastrointestinal adverse reactions. The current FDA labeling also tells healthcare providers to consider a patient’s history of severe stomach problems, including gastroparesis.
However, there is an important difference between:
“Ozempic can affect stomach emptying”
and
“Ozempic causes permanent gastroparesis in every person who develops it.”
The latter has not been established.
The lawsuits are focused partly on whether the manufacturers adequately warned about the possibility of serious gastrointestinal injuries and whether particular patients’ injuries were caused by the drugs.
What Does the Ozempic Lawsuit Allege?
Plaintiffs in the litigation generally allege that:
- They used a GLP-1 medication.
- They subsequently developed serious gastrointestinal problems.
- The medication contributed to or caused their injuries.
- The manufacturers knew or should have known about these risks.
- The warnings were allegedly inadequate.
- They suffered medical expenses and other damages.
The federal MDL court describes the common allegations as involving whether defendants knew or should have known about potential gastroparesis and other gastrointestinal injuries and whether they adequately warned patients and physicians.
Novo Nordisk and Eli Lilly deny the allegations.
Which Drugs Are Included?
The federal gastrointestinal-injury MDL includes several GLP-1 drugs.
For Novo Nordisk, these include:
- Ozempic
- Wegovy
- Rybelsus
The litigation also includes certain Eli Lilly medications, including:
- Trulicity
- Mounjaro
The federal court specifically identifies these medications in its description of MDL 3094.
This means the litigation is broader than an “Ozempic lawsuit.”
Ozempic and Wegovy Are Both Semaglutide
Ozempic and Wegovy both contain semaglutide, although they are approved for different uses and have different dosing and labeling.
Because of this, lawsuits involving Wegovy and Ozempic can overlap when plaintiffs allege gastrointestinal injuries associated with semaglutide.
The FDA’s current Ozempic labeling specifically warns about severe gastrointestinal adverse reactions and states that Ozempic is not recommended for patients with severe gastroparesis.
What Is MDL 3094?
MDL stands for Multidistrict Litigation.
MDL 3094 is the federal proceeding titled:
In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation (GI Injuries).
It is being handled in the U.S. District Court for the Eastern District of Pennsylvania.
The purpose of an MDL is to coordinate lawsuits that involve common factual questions.
Instead of thousands of similar cases proceeding independently through different federal courts, certain pretrial matters can be handled together.
The individual plaintiffs still generally retain their individual claims.
How Many Ozempic Lawsuits Are There?
The litigation has grown substantially.
The exact number of cases changes as new lawsuits are filed and cases are transferred or resolved.
Recent 2026 reporting has described more than 3,700 cases consolidated in the federal gastrointestinal-injury MDL.
It is important to understand that this number represents the broader GLP-1 gastrointestinal litigation, not necessarily only people who took Ozempic.
The MDL includes multiple drugs and multiple types of alleged gastrointestinal injuries.
What Other Injuries Are Alleged?
Gastroparesis is one of the major claims, but it is not the only alleged injury.
The litigation also involves allegations concerning:
- Ileus
- Intestinal obstruction
- Severe vomiting
- Other gastrointestinal complications
- Gallbladder-related injuries
The federal MDL encompasses claims involving gastrointestinal injuries associated with the GLP-1 medications covered by the proceeding.
Is There an Ozempic Lawsuit Settlement?
No final settlement has been announced for the federal Ozempic/GLP-1 stomach-paralysis litigation.
This is important because many websites use headlines such as:
- “Ozempic lawsuit settlement”
- “Ozempic $1 million payout”
- “Ozempic settlement check”
- “Ozempic lawsuit payout 2026”
These headlines do not mean that a court-approved settlement currently exists.
The federal MDL remains litigation rather than a completed settlement program.
How Much Could an Ozempic Lawsuit Pay?
There is currently no fixed Ozempic stomach-paralysis settlement amount.
If individual cases eventually settle or receive judgments, compensation could depend on factors such as:
- Severity of the injury
- Medical expenses
- Hospitalizations
- Length of treatment
- Lost income
- Long-term effects
- Evidence connecting the drug to the injury
- Individual circumstances
- Applicable state law
Therefore, claims that every Ozempic user with gastroparesis will receive a specific amount are misleading.
Can You File an Ozempic Lawsuit?
Potential eligibility depends on the specific facts.
A person may want to speak with a qualified product-liability attorney if they used Ozempic or another relevant GLP-1 drug and developed a serious gastrointestinal condition.
Factors an attorney may examine include:
- Which medication was taken
- When treatment started
- How long the medication was used
- Dose and dosage changes
- When symptoms began
- Medical diagnosis
- Other possible causes
- Hospital records
- Medical treatment
- Whether symptoms continued after stopping the medication
A diagnosis alone does not automatically establish legal liability.
What Evidence May Be Important?
People considering a potential claim should preserve their medical records.
Useful documents can include:
- Prescription records
- Pharmacy records
- Doctor’s notes
- Hospital records
- Gastroenterology records
- Imaging and test results
- Gastroparesis diagnosis
- Medication history
- Medical bills
- Insurance records
- Records showing when Ozempic was started and stopped
A detailed timeline can also be helpful.
For example:
Started Ozempic → dose increased → symptoms developed → medical evaluation → gastroparesis diagnosed → treatment received
An attorney can use the medical history to evaluate whether the alleged injury may be connected to the medication.
Does the FDA Say Ozempic Causes Gastroparesis?
The FDA labeling recognizes that Ozempic affects gastrointestinal function and contains warnings about severe gastrointestinal adverse reactions.
The current label states that Ozempic is not recommended for patients with severe gastroparesis.
The label also instructs patients to tell their healthcare provider if they have severe stomach problems such as slowed stomach emptying or problems digesting food.
However, FDA labeling and the pending lawsuits should not be interpreted as a finding that every case of gastroparesis in an Ozempic user was caused by the medication.
Is Gastroparesis Permanent?
Not necessarily.
The course of gastroparesis can vary considerably from person to person.
Some people may improve, while others can experience persistent symptoms.
Whether an individual’s condition is temporary or long-lasting depends on the underlying cause and other medical factors.
If someone taking Ozempic develops persistent vomiting, severe abdominal symptoms, dehydration or difficulty keeping food or liquids down, they should seek medical attention rather than relying on information about the lawsuit.
What Is the Ozempic Lawsuit Status in 2026?
As of August 2026, the major federal gastrointestinal litigation is still active.
The cases are consolidated under MDL 3094 in the Eastern District of Pennsylvania. The litigation includes Ozempic and other GLP-1 medications and focuses on alleged gastrointestinal injuries, including gastroparesis.
There is currently:
- No final settlement
- No approved settlement payout
- No universal payment amount
- No general settlement claim form
- No guarantee that every Ozempic user qualifies
The litigation is still developing.
Ozempic Lawsuit vs. Ozempic Recall
These are two different things.
An Ozempic lawsuit involves legal claims by people who allege they were injured.
An FDA recall involves a safety or quality issue with a particular drug product or lot.
The existence of lawsuits does not automatically mean that Ozempic has been recalled.
Consumers should check the FDA or manufacturer’s official information for current recall information rather than assuming a lawsuit means the drug is recalled.
Frequently Asked Questions
What is the Ozempic stomach paralysis lawsuit?
It is part of federal litigation alleging that Ozempic and other GLP-1 medications can cause serious gastrointestinal injuries, including gastroparesis, and that manufacturers failed to provide adequate warnings.
What is stomach paralysis?
“Stomach paralysis” is a common description of gastroparesis, a condition involving delayed stomach emptying.
Does Ozempic cause gastroparesis?
Ozempic affects gastric emptying, and the FDA warns about severe gastrointestinal adverse reactions and says it is not recommended for patients with severe gastroparesis. However, whether Ozempic caused a particular person’s gastroparesis is an individual medical and legal question.
Is there an Ozempic settlement?
There is currently no final settlement for the federal Ozempic stomach-paralysis litigation.
How much is the Ozempic lawsuit worth?
There is no official settlement amount or guaranteed payout at this time.
Can I join the Ozempic lawsuit?
Potential eligibility depends on your medication history, diagnosis, timing, medical records and other facts. A qualified attorney can evaluate an individual claim.
What is MDL 3094?
MDL 3094 is the federal multidistrict litigation in Pennsylvania coordinating lawsuits involving alleged gastrointestinal injuries from certain GLP-1 medications, including Ozempic, Wegovy and Rybelsus.
Bottom Line
The Ozempic stomach paralysis lawsuit involves allegations that Ozempic and other GLP-1 medications can cause serious gastrointestinal injuries, particularly gastroparesis, and that manufacturers did not adequately warn patients and doctors about these risks.
The federal cases have been consolidated into MDL 3094 in the Eastern District of Pennsylvania. The litigation includes Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro-related claims.
The FDA’s current Ozempic labeling recognizes severe gastrointestinal adverse reactions and states that Ozempic is not recommended for patients with severe gastroparesis.
However, there is no final Ozempic stomach-paralysis settlement or guaranteed payout as of August 2026. The lawsuits remain unresolved, and the allegations against the manufacturers have not been established as final court findings.